Stocktwits on MSN
Theriva™ Biologics licenses SYN-020 to Rasayana Therapeutics for multiple indications
Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results